Cited by 136TGF-β signaling in diseasesLiver physiology and pathologyInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

TGFβ2 and TGFβ3 isoforms drive fibrotic disease pathogenesis

Open access
Sun, Tianhe, Huang, Zhiyu, Liang, Wei-Ching, Yin, Jianping, Lin, Wei Yu, Wu, Jia, Vernes, Jean-Michel, Lutman, Jeff +27 more·2021·Science Translational Medicine

Abstract

TGFβ2 and TGFβ3 isoforms are activated via unique mechanisms and are associated with fibrosis in human diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.abe0407

Cites

91 of 91 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A recent study implicates TGFβ2 and TGFβ3 as potent fibrogenic stimuli that lack the pro-inflammatory effects of TGFβ1 antagonism.

    “Although studies have long implicated TGFβ1 as the dominant fibrogenic driver, a recent study also implicates TGFβ2 and TGFβ3 as potent fibrogenic stimuli, but which lack the pro-inflammatory effects of TGFβ1 antagonism that have limited the latter’s appeal as a therapeutic target (147).”
  • TGFβ1 was the first and remains the most potent fibrogenic stimulus towards HSCs and other tissue myofibroblasts, but TGFβ2 and TGFβ3 merit consideration as safer therapeutic targets.

    “TGFβ1 was the first, and remains the most potent fibrogenic stimulus towards HSCs and other tissue myofibroblasts, but as noted above, TGFβ2 and TGFβ3 merit consideration as safer therapeutic targets (147).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Sun, T., Huang, Z., Liang, W.-C., Yin, J., Lin, W. Y., Wu, J., Vernes, J.-M., Lutman, J., Caplazi, P., Jeet, S., Wong, T., Wong, M., DePianto, D. J., Morshead, K. B., Sun, K.-H., Modrusan, Z., Vander Heiden, J. A., Abbas, A. R., Zhang, H., Xu, M., N’Diaye, E.-N., Roose-Girma, M., Wolters, P. J., Yadav, R., Sukumaran, S., Ghilardi, N., Corpuz, R., Emson, C., Meng, Y. G., Ramalingam, T. R., Lupardus, P., Brightbill, H. D., Seshasayee, D., Wu, Y., & Arron, J. R.
Affiliations
  • Genentech (US)
  • Department of Antibody Engineering, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
  • Department of OMNI Bioinformatics, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
  • University of California, San Francisco (US)
Corresponding author
  • Sun, Tianhe
  • Arron, Joseph R.
Venue
Science Translational Medicine
Published
2021-08-04
Volume
13
Issue
605
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W3188006245
Cited by
134
References
91
Citations by year
2026: 21 · 2025: 33 · 2024: 24 · 2023: 38 · 2022: 16 · 2021: 2
FWCI
6.43
Type
journal article
Language
en
Open access
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
Genentech (N/A)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Keywords
TGF-beta2, TGF-beta3, fibrosis, pulmonary fibrosis, liver fibrosis, allosteric inhibition, TGF-β1, conditional knockout mice, co-crystal structure, antifibrotic therapy
MeSH terms
Animals, Disease Models, Animal, Female, Fibrosis, Humans, Protein Isoforms, Mice, Transforming Growth Factor beta2, Transforming Growth Factor beta3

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review